Primary prevention of ischemic stroke: A statement for healthcare professionals from the stroke council of the American Heart Association

Stroke

Volumn 32, Issue 1, 2001, Pages 280-299

  Goldstein, L B ^a   Adams, R ^a   Becker, K ^a   Furberg, C D ^a   Gorelick, P B ^a   Hademenos, G ^a   Hill, M ^a   Howard, G ^a   Howard, V J ^a   Jacobs, B ^a   Levine, S R ^a   Mosca, L ^a   Sacco, R L ^a   Sherman, D G ^a   Wolf, P A ^a   Del Zoppo, G J ^a  

^a NONE

Author keywords

AHA Scientific Statements; Arrhythmia; Hypercholesterolemia; Prevention; Risk factors; Smoking; Stroke

Indexed keywords

CEREBROVASCULAR ACCIDENT; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE;

EID: 0035151363     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.32.1.280     Document Type: Review

References (330)

1. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks
2. Stroke prevention
3. American Heart Association Prevention Conference IV: Prevention and rehabilitation of stroke: Risk factors
4. Stroke risk profile: Adjustment for antihypertensive medication: The Framingham Study
5. The end of the long-term decline in stroke mortality in the United States?
6. Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota, through 1989
7. Modeling of risk factors for ischemic stroke: The Willis Lecture
8. Secular trends in stroke incidence and mortality: The Framingham Study
9. Stroke incidence among white, black, and Hispanic residents of an urban community: The Northern Manhattan Stroke Study
10. Stroke in women: The 1997 Paul Dudley White International Lecture
11. Pregnancy and the risk of stroke
12. Number of pregnancies and risk for stroke and stroke subtypes
13. Cardiovascular disease in women: A statement for healthcare professionals from the American Heart Association Writing Group
14. Cerebrovascular disease in African Americans
15. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks: The National Longitudinal Mortality Study
16. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort
17. Determinants of black-white differences in the risk of cerebral infarction: The National Health and Nutrition Examination Survey Epidemiologic Follow-up Study
18. Secular trends in stroke mortality in African Americans: The role of urbanization, diabetes and obesity
19. Stroke mortality in blacks: Disturbing trends
20. Stroke recurrence is more frequent in blacks and Hispanics
21. Differences in stroke between white, Hispanic, and Native American patients: The Barrow Neurological Institute stroke database
22. Stroke in the People's Republic of China, I: Geographic variations in incidence and risk factors
23. Analysis of risk factors for stroke in a cohort of men born in 1913
24. Familial aggregation of stroke: The Framingham Study
25. Familial history of stroke and stroke risk: The Family Heart Study
26. The study of human twins in medical research
27. A study of twins and stroke
28. Cerebrovascular risk
29. Blood pressure, stroke, and coronary heart disease, part 1: Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias
30. Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991
31. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
32. Effects of treatment on morbidity in hypertension, II: Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg
33. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg
34. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis
35. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators
36. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP)
37. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: Data from the health examination surveys, 1960 to 1991
38. Excess stroke among hypertensive men and women attributable to undertreatment of hypertension
39. Antihypertensive medication compliance in African-American stroke patients: Behavioral epidemiology and interventions
40. Short- and long-term effects of smoking on arterial wall properties in habitual smokers
41. Acute effects of smoking on blood pressure and cerebral blood flow
42. Meta-analysis of relation between cigarette smoking and stroke
43. Probability of stroke: A risk profile from the Framingham Study
44. Smoking cessation and decreased risk of stroke in women
45. Cigarette smoking and stroke in a cohort of U.S. male physicians
46. Cigarette smoking as a risk factor for stroke: The Framingham study
47. Smoking cessation and the risk of stroke in middle-aged men
48. Passive smoking as a cause of heart disease
49. Passive smoking as well as active smoking increases the risk of acute stroke
50. Insulin and coronary artery disease: Is syndrome X the unifying hypothesis?
51. Clinical implications of the insulin resistance syndrome
52. Glucose intolerance and 22-year stroke incidence: The Honolulu Heart Program
53. Diabetes and cardiovascular disease: The Framingham Study
54. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
55. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial
56. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group
57. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
58. Diabetes and glucose intolerance as risk factors for stroke
59. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
60. Clinical practice recommendations 1998
61. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study: The CHS Collaborative Research Group
62. Precursors of extracranial carotid atherosclerosis in the Framingham Study
63. Outcome in patients with asymptomatic neck bruits
64. Asymptomatic tight stenosis of the internal carotid artery: Long-term prognosis
65. Causes and severity of ischemic stroke in patients with internal carotid artery stenosis
66. The causes and risk of stroke in patients with asymptomatic internal carotid artery stenosis
67. Stroke risk in patients with carotid stenosis
68. Carotid surgery versus medical therapy in asymptomatic carotid stenosis
69. Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis
70. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis: The Veterans Affairs Cooperative Study Group
71. Endarterectomy for asymptomatic carotid artery stenosis
72. Multicenter review of preoperative risk factors for endarterectomy for asymptomatic carotid artery stenosis
73. US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke: Design, service availability, and common practices
74. Complication rates for carotid endarterectomy: A call for action
75. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study
76. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study
77. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study
78. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
79. Stroke prevention in atrial fibrillation study: Final results
80. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators
81. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study
82. Antithrombotic therapy in atrial fibrillation
83. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
84. Cardiac investigation in patients with cerebrovascular disease
85. Coronary artery disease in patients with cerebrovascular disease: A prospective study
86. Fatal myocardial infarction following carotid endarterectomy: Three hundred thirty-five patients followed 6-11 years after operation
87. Predicting discharge status at commencement of stroke rehabilitation
88. Myocardial infarction and stroke
89. Asymptomatic coronary artery disease in patients with stroke: Prevalence, prognosis, diagnosis, and treatment
90. Frequency and severity of asymptomatic coronary disease in patients with different causes of stroke
91. Frequency and prognostic significance of silent coronary artery disease in patients with cerebral ischemia undergoing carotid endarterectomy
92. Cerebral ischemia and asymptomatic coronary artery disease: A prospective study of 83 patients
93. Cardiac disorders and stroke
94. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIb trial: Thrombolysis In Myocardial Ischemia
95. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
96. Stroke in patients with acute coronary syndromes: Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial
97. Stroke following coronary artery bypass grafting: A ten-year study
98. Stroke following coronary-artery bypass surgery: A case control estimate of the risk from carotid bruits
99. Stroke in coronary artery bypass graft surgery: An analysis of the CASS experience
100. Differential effects of advanced age on neurologic and cardiac risks of coronary artery operations
101. Risk factors for stroke after cardiac surgery: Buffalo Cardiac-Cerebral Study Group
102. Multicenter preoperative stroke risk index for patients undergoing coronary artery bypass graft surgery: Multicenter Study of Perioperative Ischemia (MCSPI) Research Group
103. Adverse cerebral outcomes after coronary bypass surgery: Multicenter Study of Perioperative Ischemic Research Group and the Ischemia Research and Education Foundation Investigators
104. Outcomes of cardiac surgery in patients > or =80 years: Results from the National Cardiovascular Network
105. Outcomes of coronary artery bypass graft surgery in 24,461 patients aged 80 years or older
106. Risk factors for early or delayed stroke after cardiac surgery
107. Stroke in cardiac surgical patients: Determinants and outcome
108. Protruding aortic arch atheromas: Risk of stroke during heart surgery with and without aortic arch endarterectomy
109. Atherosclerosis of the ascending aorta is an independent predictor of long-term neurologic events and mortality
110. Neurological complications
111. Cerebrovascular accidents in sickle cell disease: Rates and risk factors
112. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease: Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease
113. The use of transcranial ultrasonography to predict stroke in sickle cell disease
114. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler
115. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography
116. Transfusion management of sickle cell disease
117. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia
118. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia
119. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts: Prospective Studies Collaboration
120. Multivariate analysis of risk factors for stroke: Eight-year follow-up study of farming villages in Akita, Japan
121. Factors related to stroke incidence in Hawaii Japanese men: The Honolulu Heart Study
122. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: The Copenhagen City Heart Study
123. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men: Implications of shared risk
124. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial
125. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes
126. High density lipoprotein: A potentially modifiable stroke risk factor: The Northern Manhattan Stroke Study
127. Elevated high density lipoprotein levels are more important in atherosclerotic ischemic stroke subtypes: The Northern Manhattan Stroke Study
128. Prevalence of carotid atherosclerosis and serum cholesterol levels in eastern Finland
129. Thickness of carotid artery atherosclerotic plaque and ischemic risk
130. Carotid atherosclerosis measured by B-mode ultrasound in populations: Associations with cardiovascular risk factors in the ARIC study
131. Cholesterol reduction and the risk for stroke in men: A meta-analysis of randomized, controlled trials
132. Beneficial effects of colestipol-niacin therapy on the common carotid artery: Two- and four-year reduction of intima-media thickness measured by ultrasound
133. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events: Asymptomatic Carotid Artery Progression Study (ACAPS) research group
134. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)
135. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: A randomized controlled clinical trial
136. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
137. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events trial investigators
138. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group
139. Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program
140. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
141. Stroke, statins, and cholesterol: A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-Co-A reductase inhibitors
142. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
143. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study
144. Systematic review on the risk and benefit of different cholesterol-lowering interventions
145. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
146. Vascular effects of statins in stroke
147. Stroke protection by 3-hydroxy-3methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
148. Long-term effects of pravastatin on plasma concentration of C-reactive protein: The Cholesterol And Recurrent Events (CARE) Investigators
149. Neuroprotective properties of statins in cerebral ischemia and stroke
150. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
151. Association of levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography
152. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women
153. Lipoprotein(a) and ischemic cerebrovascular disease in young adults
154. Relationship between lipoprotein(a) and both stroke and carotid atheroma
155. Lipoprotein(a) and apolipoprotein E epsilon 4 as independent risk factors for ischemic stroke
156. Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions: Results from a nested case-control study in northern Sweden
157. Body size and fat distribution as predictors of stroke among US men
158. A prospective study of body mass index, weight change, and risk of stroke in women
159. Exercise in the prevention of stroke
160. Physical activity in older middle-aged men and reduced risk of stroke: The Honolulu Heart Program
161. Physical activity and stroke risk: The Framingham Study
162. Risk factors of stroke incidence and mortality: A 12-year follow-up of the Oslo Study
163. Physical activity and incidence of coronary heart disease and stroke in women
164. Lifestyle factors and risk of cerebrovascular disease in women: The Copenhagen City Heart Study
165. Physical activity and stroke incidence in women and men: The NHANES I Epidemiologic Follow-up Study
166. Leisure-time physical activity and ischemic stroke risk: The Northern Manhattan Stroke Study
167. Physical activity and stroke in British middle aged men
168. Lifelong exercise and stroke
169. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension
170. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women
171. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women
172. Moderate to high intensity conditioning leisure time physical activity and high cardiorespiratory fitness are associated with reduced plasma fibrinogen in eastern Finnish men
173. Effects of exercise training and deconditioning on platelet function in men
174. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients
175. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners
176. Physical activity and cardiovascular health: NIH Consensus Development Panel on Physical Activity and Cardiovascular Health
177. Physical activity and public health: A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine
178. Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States
179. Fruit and vegetable intake in relation to risk of ischemic stroke
180. Alcohol and hemorrhagic stroke: The Honolulu Heart Program
181. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women
182. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community
183. Does ethanol intoxication promote brain infarction in young adults?
184. The status of alcohol as a risk factor for stroke
185. Is acute alcohol ingestion a risk factor for ischemic stroke? Results of a controlled study in middle-aged and elderly stroke patients at three urban medical centers
186. Stroke incidence and risk factors for stroke in Copenhagen, Denmark
187. Alcohol consumption: A risk factor for hemorrhagic and non-hemorrhagic stroke
188. Alcohol use and subsequent cerebrovascular disease hospitalizations
189. Regular light-to-moderate intake of alcohol and the risk of ischemic stroke: Is there a beneficial effect?
190. The protective effect of moderate alcohol consumption on ischemic stroke
191. Alcohol and stroke: A case-control study of drinking habits past and present
192. Stroke and alcohol consumption
193. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence
194. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum
195. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the Nutrition Committee, American Heart Association
196. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population
197. Serum total homocysteine concentrations in adolescent and adult Americans: Results from the third National Health and Nutrition Examination Survey
198. Serum total homocysteine concentrations in the Third National Health and Nutrition Examination Survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentrations
199. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes
200. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: Results from the Third National Health and Nutrition Examination Survey, 1988-1994
201. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study
202. Homocysteine as a risk factor for ischemic stroke: An epidemiological story in evolution
203. Homocysteine, hypertension and stroke
204. Blood levels of homocysteine and increased risks of cardiovascular disease: Causal or casual?
205. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
206. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease
207. Emergence of recreational drug abuse as a major risk factor for stroke in young adults
208. Cerebrovascular complications of the use of the "crack" form of alkaloidal cocaine
209. Stroke associated with cocaine use
210. Occurrence of stroke associated with use/abuse of drugs
211. Crack cocaine rise and stroke in young patients
212. Illicit drug-associated ischemic stroke in the Baltimore-Washington Young Stroke Study
213. Cerebral infarction in young adults: The Baltimore-Washington Cooperative Young Stroke Study
214. Stroke and cocaine or amphetamine use
215. Methamphetamine-related stroke: Four cases
216. Cocaine-induced erythrocytosis and increase in von Willebrand factor: Evidence for drug-related blood doping and prothrombotic effects
217. The management of thrombosis in the antiphospholipid-antibody syndrome
218. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients
219. Ischemic stroke: Recognizing risks unique to women
220. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: The Framingham Study
221. Postmenopausal estrogen replacement: A long-term cohort study
222. Postmenopausal hormone therapy and mortality
223. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy
224. The role of estrogens as a risk factor for stroke in postmenopausal women
225. Decreased risk of stroke among postmenopausal hormone users
226. Hormone replacement therapy and the risk of stroke: Follow-up of a population-based cohort in Sweden
227. Cause-specific mortality in women receiving hormone replacement therapy
228. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
229. Ischemic stroke and use of estrogen and estrogen/progestogen as hormone replacement therapy
230. Decreased mortality in users of estrogen replacement therapy
231. Postmenopausal oestrogen treatment and stroke: A prospective study
232. Noncontraceptive estrogens and mortality: Long-term follow-up of women in the Walnut Creek Study
233. Persantine aspirin trial in cerebral ischemia, part III: Risk factors for stroke
234. Hormone therapy to prevent disease and prolong life in postmenopausal women
235. Oral contraceptives and stroke in young women: Associated risk factors
236. Oral contraception and stroke: Evidence from the Royal College of General Practitioners' Oral Contraception Study
237. Oral contraception and risk of a cerebral thromboembolic attack: Results of a case-control study
238. Ischaemic stroke combined oral contraceptives: Results of an international, multicentre, case-control study: WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
239. Use of low-dose oral contraceptives and stroke in young women
240. Stroke in users of low-dose oral contraceptives
241. Case-control study of oral contraceptives and risk of thromboembolic stroke: Results from International Study on Oral Contraceptives and Health of Young Women
242. Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study: WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
243. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: The influence of diabetes, hypertension, migraine and previous thrombotic disease
244. Ischemic stroke risk with oral contraceptives: A meta-analysis
245. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation
246. Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium
247. Flow stimulates ICAM-1 expression time and shear stress dependently in cultured human endothelial cells
248. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells
249. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque
250. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines
251. Inflammation in high-grade carotid stenosis: A possible role for macrophages and T cells in plaque destabilization
252. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis
253. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk in Communities (ARIC) study
254. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis
255. Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction
256. Multiple infections in carotid atherosclerotic plaques
257. Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis
258. Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery
259. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery
260. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis
261. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: A prospective study in middle-aged to elderly men with treated hypertension
262. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis: Atherosclerosis Risk in Communities (ARIC) Study Investigators
263. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: The West Birmingham Stroke Project
264. Association of chlamydial infection with cerebrovascular disease
265. Chlamydia pneumoniae eradication from carotid plaques: Results of an open, randomised treatment study
266. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke
267. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
268. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men
269. Prospective study of C-reactive protein and the risk of future cardiovascular events among healthy women
270. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
271. Effect of short-term aspirin use on C-reactive protein
272. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol And Recurrent Events (CARE) Investigators
273. Stroke risk factors prepare rat brainstem tissues for modified local Shwartzman reaction
274. Guidelines for the management of patients with acute ischemic stroke: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association
275. Effectiveness versus efficacy of treatment of hypertension for stroke prevention
276. Cost-effectiveness of screening for asymptomatic carotid stenosis
277. Prevalence of asymptomatic carotid disease: Results of duplex scanning in 348 unselected volunteers
278. The efficacy of aspirin in patients with atrial fibrillation: Analysis of pooled data from 3 randomized trials
279. Prevalence and determinants of carotid atherosclerosis in a general population
280. Prevalence of extracranial carotid artery disease detectable by echo-Doppler in an elderly population
281. Prevalence of extracranial carotid artery disease: A survey of an asymptomatic population with noninvasive techniques
282. Vascular event rates in patients with atherosclerotic cerebrovascular disease
283. Sickle cell disorders and cerebrovascular disease
284. Stroke prevention: Windows of opportunity and failed expectations? A discussion of modifiable cardiovascular risk factors and a prevention proposal
285. The spread of the obesity epidemic in the United States, 1991-1998
286. Anticardiolipin antibodies in normal subjects: Neuropsychological correlates and MRI findings
287. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population
288. Antiphospholipid antibodies in predicting adverse pregnancy outcome: A prospective study
289. Antiphospholipid antibodies in pregnancy: Prevalence and clinical associations
290. Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening
291. High prevalence of factor V Leiden in healthy Jordanian Arabs
292. Activated protein C resistance and the FV:R506Q mutation in a random population sample: Associations with cardiovascular risk factors and coagulation variables
293. World distribution of factor V Leiden
294. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors
295. Thrombophilia as a multigenic disease
296. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR
297. Venous Thrombosis: From Genes to Clinical Medicine
298. Prevalence of factor V Leiden mutation in non-European populations
299. Aspiration following stroke: Clinical correlates and outcome
300. Rehabilitation for stroke: A review
301. Prevalence of the G20210A polymorphism in the 3′-untranslated region of the prothrombin gene in different human populations
302. Geographic distribution of the 20210 G to A prothrombin variant
303. Prevalence of protein C deficiency in the healthy population
304. Prevalence of antithrombin deficiency in the healthy population
305. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke
306. Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset
307. The frequency of phospholipid antibodies in an unselected stroke population
308. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity
309. Anticardiolipin antibodies in ischemic stroke in the young: Indian experience
310. Beta-2-glycoprotein 1-dependent (B2GP1-dep) anticardiolipin antibodies (aCL) are an independent risk factor for ischemic stroke in the Honolulu Heart Cohort
311. The transition G to A at position 20210 in the 3′-untranslated region of the prothrombin gene is not associated with cerebral ischemia
312. C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: A case-control study
313. Inherited prothrombotic conditions and premature ischemic stroke: Sex difference in the association with factor V Leiden
314. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
315. Inherited abnormalities of blood coagulation in juvenile stroke
316. The prothrombin G20210A mutation and factor V Leiden mutation in patients with cerebrovascular disease
317. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men
318. The venous thrombosis risk factor 20210A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease
319. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients
320. Prospective study of markers of hemostatic function with risk of ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) Study Investigators
321. Cerebral thrombosis and oral contraceptives: A case-control study
322. Guidelines for carotid endarterectomy: A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association
323. Consensus against both endarterectomy and routine screening for asymptomatic carotid artery stenosis: Canadian Stroke Consortium
324. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)